Review article: Hepatitis vaccination in patients with chronic liver disease

Alimentary Pharmacology and Therapeutics

Volumn 19, Issue 7, 2004, Pages 715-727

  Reiss, G ^a   Keeffe, E B ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; BILIRUBIN; HEPATITIS A HEPATITIS B VACCINE; HEPATITIS A VACCINE; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; RECOMBINANT HEPATITIS B VACCINE; VIRUS DNA;

CANCER INCIDENCE; CHRONIC LIVER DISEASE; CLINICAL TRIAL; DEATH; DISEASE CARRIER; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEVER; HEADACHE; HEPATITIS A; HEPATITIS A VIRUS; HEPATITIS B; HEPATITIS B VIRUS; HISTOLOGY; HUMAN; IMMUNITY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MORTALITY; NAUSEA; PRIORITY JOURNAL; REVIEW; SEROCONVERSION; SIDE EFFECT; SUPERINFECTION;

ACUTE DISEASE; CHRONIC DISEASE; HEPATITIS A; HEPATITIS A VACCINES; HEPATITIS B VACCINES; HEPATITIS B, CHRONIC; HUMANS; LIVER DISEASES; SUPERINFECTION;

EID: 1942438217     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2004.01906.x     Document Type: Review

References (95)

1. Schiff ER. Viral hepatitis. In: Schiff ER, Sorrell MF, Maddrey WC, eds. Diseases of the Liver, 9th edn. Philadelphia: Lippincott Williams & Wilkins, 2003: 741-4.
2. Lok AS. Chronic hepatitis B. N Engl J Med 2002; 346: 1682-3.
3. World Health Organization. Fact Sheet No. 164: Hepatitis C. Available at: http://www.who.int. Accessed November 14 2003.
4. Kozak LJ, Hall MJ, Owings MF. National hospital discharge survey: 2000 annual summary with detailed diagnosis and procedure data. National Center for Health Statistics. Vital Health Stat 2003; 13: 1-212.
5. Arias E, Anderson RN, Kung HC, Murphy SL, Kochanek KD. Deaths: final data for 2001. Natl Vital Stat Rep 2003; 52: 1-115.
6. United Network for Organ Sharing (UNOS). Donors and Waiting List: 1993-2002 National Data. Available at: http:// www.unos.org/data/default.asp? displayType=usData. Accessed November 14 2003.
7. Centers for Disease Control and Prevention. Recommendations and reports: hepatitis A and B vaccines. MMWR 2003: 52(RR01): 34-6.
8. National Institutes of Health. National Institutes of Health Consensus Development Conference statement: management of hepatitis C: 2002 - June 10-12, 2002. Hepatology 2002; 36(Suppl. 1): S3-20.
9. Lemon SM. An overview of the molecular virology and pathogenesis of type A viral hepatitis. In: Rizzetto M, Purcell RH, Gerin JL, Verme G, eds. Viral Hepatitis and Liver Disease. Turin: Edzioniz Minerva Medica, 1997: 3-8.
10. Willner IR, Uhl MD, Howard SC, Williams EQ, Riely CA, Waters B. Serious hepatitis A. An analysis of patients hospitalized during an urban epidemic in the United States. Ann Intern Med 1998; 128: 111-4.
11. McNeill M, Hoy JF, Richards MJ, et al. Aetiology of fatal hepatitis in Melbourne: a retrospective study. Med J Aust 1984; 141: 637-40.
12. Keeffe EB. Is hepatitis A more severe in patients with chronic hepatitis B and other chronic liver diseases? Am J Gastroenterol 1995; 90: 201-5.
13. Yao G. Clinical spectrum and natural history of viral hepatitis in a 1988 Shanghai epidemic. In: Hollinger FB, Lemon SM, Margolis H, eds. Viral Hepatitis and Liver Disease. Baltimore: Lippincott Williams & Wilkins, 1991: 76-8.
14. Hadler SC. Global impact of hepatitis A virus infection changing patterns. In: Hollinger FB, Lemon SM, Margolis H, eds. Viral Hepatitis and Liver Disease. Baltimore: Lippincott, Williams & Wilkins, 1990: 14-20.
15. Nair S, Perrillo RP, Hepatitis B and D. In: Zakim D. Boyer T. eds. Hepatology. A Textbook of Liver Disease, 4th edn. Philadelphia: Saunders, 2003: 959-1004.
16. Fukumoto Y, Okita K, Konishi T, et al. Hepatitis A infection in chronic carriers of hepatitis B virus. In: Sung J-L, Chen D-S, eds. Viral Hepatitis and Hepatocellular Carcinoma. Amsterdam: Excerpta Medica, 1990: 43-8.
17. Papachristou AA, Dumas AS, Katsouyannopoulos VC. Dissociation of alanine aminotransferase values in acute hepatitis A patients with and without past experience to the hepatitis B virus. Epidemiol Infect 1991; 106: 397-402.
18. Pramoolsinsap C, Poovorawan Y, Hirsch P, Busagorn N, Attamasirikul K. Acute hepatitis-A super-infection in HBV carriers, or chronic liver disease related to HBV or HCV. Ann Trop Med Parasitol 1999; 93: 745-51.
19. Yang CY, Chu CM, Liaw YF, et al. A clinical study on acute hepatitis A with special reference to its occurrence in HBsAg carriers. J Formos Med Assoc 1983; 82: 1126-32.
20. Rezende G, Roque-Afonso AM, Samuel D, et al. Viral and clinical factors associated with the fulminant course of hepatitis A infection. Hepatology 2003; 38: 613-8.
21. Tassopoulos N, Papaevangelou G, Roumeliotou-Karayannis A, et al. Double infections with hepatitis A and B viruses. Liver 1985; 5: 348-53.
22. Zachoval R, Roggendorf M, Deinhardt F. Hepatitis A infection in chronic carriers of hepatitis B virus. Hepatology 1983; 3: 528-31.
23. Viola LA, Barrison IG, Coleman JC, Murray-Lyon IM. The clinical course of acute type A hepatitis in chronic HBsAg carriers: a report of 3 cases. Postgrad Med J 1982; 58: 80-1.
24. Conteas C, Kao H, Rakela J, Weliky B. Acute type A hepatitis in three patients with chronic HBV infection. Dig Dis Sci 1983; 28: 684-6.
25. Vento S, Garofano T, Renzini C, et al. Fulminant hepatitis associated with hepatitis A superinfection in patients with chronic hepatitis C. N Engl J Med 1998; 338: 286-90.
26. Mele A, Tosti ME, Stroffolini T. Hepatitis associated with hepatitis A superinfection in patients with chronic hepatitis C (letter). N Engl J Med 1998; 338: 1771.
27. Leino T, Pebody R, Leinikki P. Hepatitis associated with hepatitis A superinfection in patients with chronic hepatitis C (letter). N Engl J Med 1998; 338: 1772.
28. Hasle G, Hoel T, Jensenius M. Mortality of hepatitis A in adults with hepatitis C antibodies (letter). Lancet 1998; 351: 1888.
29. Devalle S, de Paula VS, de Oliveira JM, Niel C, Gaspar AM. Hepatitis A virus infection in hepatitis C Brazilian patients. J Infect 2003; 47: 125-8.
30. Battegay M, Naef M, Bucher HC. Hepatitis associated with hepatitis A superinfection in patients with chronic hepatitis C (letter). N Engl J Med 1998; 338: 1771-2.
31. Kyrlagkitsis I, Cramp ME, Smith H, Portmann B, O'Grady J. Acute hepatitis A virus infection: a review of prognostic factors from 25 years experience in a tertiary referral center. Hepatogastroenterology 2002; 49: 524-8.
32. Akriviadis EA, Redeker AG. Fulminant hepatitis A in intravenous drug users with chronic liver disease. Ann Intern Med 1989; 110: 838-9.
33. Koff RS. Risks associated with hepatitis A and hepatitis B in patients with hepatitis C. J Clin Gastroenterol 2001; 33: 20-6.
34. Keeffe EB. Vaccination against hepatitis A and B in chronic liver disease. Viral Hepatitis Rev 1999; 5: 77-88.
35. Féray C, Gigou M, Samuel D, et al. Hepatitis C virus RNA and hepatitis B virus DNA in serum and liver of patients with fulminant hepatitis. Gastroenterology 1993; 104: 549-55.
36. Krogsgaard K, Wantzin P, Mathiesen L, Ring-Larsen H. Chronic evolution of acute hepatitis B: the significance of simultaneous infections with hepatitis C and D. Scand J Gastroenterol 1991; 26: 275-80.
37. Teuber G, Dienes HP, Meyer zum Büschenfelde KH, Gerken G. Hepatitis B virus superinfection in a patient with chronic hepatitis C receiving alpha-interferon treatment. Hepatogastroenterology 1991; 42: 189-91.
38. Liaw YF, Yeh CT, Tsai SL. Impact of acute hepatitis B virus superinfection on chronic hepatitis C virus infection. Am J Gastroenterol 2000; 95: 2978-80.
39. Wietzke P, Schott P, Braun F, Mihm S, Ramadori G. Clearance of HCV RNA in a chronic hepatitis C virus-infected patient during acute hepatitis B virus superinfection. Liver 1999; 19: 348-53.
40. Zarski JP, Bohn B, Bastle A, et al. Characteristics of patients with dual infection by hepatitis B and C viruses. J Hepatol 1998; 28: 27-33.
41. Crespo J, Lozano JL, Carte B, de las Heras B, de la Cruz F, Pons-Romero F. Viral replication in patients with concomitant hepatitis B and C virus infections. Eur J Clin Microbiol Infect Dis 1997; 16: 445-51.
42. Ohkawa K, Hayashi N, Yuki N, et al. Long-term follow-up of hepatitis B virus and hepatitis C virus replicative levels in chronic hepatitis patients coinfected with both viruses. J Med Virol 1995; 46: 258-64.
43. Pontisso P, Ruvoletto MG, Fattovich G, et al. Clinical and virological profiles in patients with multiple hepatitis virus infections. Gastroenterology 1993; 105: 1529-33.
44. Cohen J. Vaccines get a new twist. Science 1994; 264: 503-5.
45. Mohamed Ael S, al Karawi MA, Mesa GA. Dual infection with hepatitis C and B viruses: clinical and histological study in Saudi patients. Hepatogastroenterology 1997; 44: 1404-6.
46. Fuiano B, Pannullo A, Annovazzi G, et al. Risk factors and association with HBV infection in chronic C hepatitis. Ital J Gastroenterol 1992; 24: 409-11.
47. Benvegnu L, Fattovich G, Noventa F, et al. Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis. A prospective study. Cancer 1994; 74: 2442-8.
48. Alberti A, Pontisso P, Chemello L, et al. The interaction between hepatitis B virus and hepatitis C virus in acute and chronic liver disease. J Hepatol 1995; 22(1 Suppl.): 38-41.
49. Weltman MD, Brotodihardjo A, Crewe EB, et al. Coinfection with hepatitis B and C or B, C and delta viruses results in severe chronic liver disease and responds poorly to interferon-alpha treatment. J Viral Hepat 1995; 2: 39-45.
50. Ilan Y, Ashur Y, Tur-Kaspa R, Shouval D. Chronic hepatitis C virus infection with exposure to hepatitis B virus. Isr J Med Sci 1994; 30: 259-63.
51. Cacciola I, Pollicino T, Squadrito G, Cerenzia G, Orlando ME, Raimondo G. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med 1999; 341: 22-6.
52. Kao JH, Chen PJ, Lai MY, Chen DS. Occult hepatitis B virus infection and clinical outcomes of patients with chronic hepatitis C. J Clin Microbiol 2002; 40: 4068-71.
53. Shintani Y, Yotsuyanagi H, Moriya K, et al. The significance of hepatitis B virus DNA detected in hepatocellular carcinoma of patients with hepatitis C. Cancer 2000; 88: 2478-86.
54. Rodriguez-Inigo E, Mariscal L, Bartolome J, et al. Distribution of hepatitis B virus in the liver of chronic hepatitis C patients with occult hepatitis B virus infection. J Med Virol 2003; 70: 571-80.
55. Barnett ED, Holmes AH, Geltman P, Phillips SL, Harrison TS. Immunity to hepatitis A in people born and raised in endemic areas. J Travel Med 2003; 10: 11-4.
56. Dhotial A, Kapoor D, Kumar N. Seroprevalence of hepatitis A virus antibody in patients with chronic liver disease -experience from a tertiary care hospital in north India. Trop Gastroenterol 2002; 23: 170-1.
57. Xavier S, Anish K. Is hepatitis A vaccination necessary in Indian patients with cirrhosis of liver? Indian J Gastroenterol 2003; 22: 54-5.
58. Acharya SK, Batra Y, Saraya A, et al. Vaccination for hepatitis A virus is not required for patients with chronic liver disease in India. Natl Med J India 2002; 15: 267-8.
59. Batra Y, Bhatkal B, Ojha B, et al. Vaccination against hepatitis A virus may not be required for school children in northern India: results of a seroepidemiological survey. Bull WHO 2002; 80: 728-31.
60. Koff RS. Hepatitis A and E. In: Zakim D, Boyer T, eds. Hepatology: A Textbook of Liver Disease, 4th edn. Philadelphia: Saunders, 2003: 939-58.
61. Diago M, Lujan M, Garcia V, et al. Prevalence of anti-hepatitis A in patients with chronic liver disease. Gastroenterol Hepatol 1998; 21: 324-6.
62. Saab S, Lee C, Shpaner A, Ibrahim AB. Seroepidemiology of hepatitis A in patients with chronic liver disease. J Viral Hepat; in press.
63. Sjogren MH. Preventing acute liver disease in patients with chronic liver disease (editorial). Hepatology 1998; 27: 887-8.
64. Siddiqui F, Mutchnick M, Kinzie J, Peleman R, Naylor P, Ehrinpreis M. Prevalence of hepatitis A virus and hepatitis B virus immunity in patients with polymerase chain reaction-confirmed hepatitis C: implications for vaccination strategy. Am J Gastroenterol 2001; 96: 858-63.
65. Rothstein KD. Hepatitis A vaccination in patients with chronic liver disease: to screen or not to screen (editorial). Am J Gastroenterol 2002; 97: 1590-3.
66. Jacobs RJ, Koff RS, Meyerhoff AS. The cost-effectiveness of vaccinating chronic hepatitis C patients against hepatitis A. Am J Gastroenterol 2002; 97: 427-34.
67. Duncan M, Hirota WK, Tsuchida A. Prescreening versus empirical immunization for hepatitis A in patients with chronic liver disease: a prospective cost analysis. Am J Gastroenterol 2002; 97: 1792-5.
68. Clemens R, Safary A, Hepburn A, Roche C, Stanbury WJ, Andre FE. Clinical experience with an inactivated hepatitis A vaccine. J Infect Dis 1995; 171(Suppl. 1): S44-9.
69. Innis BL, Snitbhan R, Kunasol P, et al. Protection against hepatitis A by an inactivated vaccine. J Am Med Assoc 1994; 271: 1328-34.
70. Furesz J, Scheifele DW, Palkonyay L. Safety and effectiveness of the new inactivated hepatitis A virus vaccine. CMAJ 1995; 152: 343-8.
71. Keeffe EB, Iwarson S, McMahon BJ, et al. Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease. Hepatology 1998; 27: 881-6.
72. Tsang SW, Sung JJ. Inactivated hepatitis A vaccine in Chinese patients with chronic hepatitis B infection. Aliment Pharmacol Ther 1999; 13: 1445-9.
73. Smallwood GA, Coloura CT, Martinez E, Stieber AC, Heffron TG. Can patients awaiting liver transplantation elicit an immune response to the hepatitis A vaccine? Transplant Proc 2002; 34: 3289-90.
74. Dumot JA, Barnes DS, Younossi Z, et al. Immunogenicity of hepatitis A vaccine in decompensated liver disease. Am J Gastroenterol 1999; 94: 1601-4.
75. Arguedas MR, Johnson A, Eloubeidi MA, Fallon MB. Immunogenicity of hepatitis A vaccination in decompensated cirrhotic patients. Hepatology 2001; 34: 28-31.
76. Arslan M, Wiesner RH, Poterucha JJ, Zein NN. Safety and efficacy of hepatitis A vaccination in liver transplantation recipients. Transplantation 2001; 72: 272-6.
77. Koff RS. Hepatitis A, hepatitis B, and combination hepatitis vaccines for immunoprophylaxis: an update. Dig Dis Sci 2002; 47: 1183-94.
78. Lemon SM, Thomas DL. Vaccines to prevent viral hepatitis. N Engl J Med 1997; 336: 196-204.
79. Jilg W, Sieger E, Zachoval R, Schätzl H. Individuals with antibodies against hepatitis B core antigen as the only serological marker for hepatitis B infection: high percentage of carriers of hepatitis B and C virus. Dig Dis Sci 1995; 40: 8-13.
80. Berger A, Doerr HW, Rabenau HF, Weber B. High frequency of HCV infection in individuals with isolated antibody to hepatitis B core antigen. Intervirology 2000; 43: 71-6.
81. Weber B, Melchior W, Gehrke R, Doerr HW, Berger A, Rabenau H. Hepatitis B virus markers in anti-HBc only positive individuals. J Med Virol 2001; 64: 312-9.
82. McMahon BJ, Parkinson AJ, Helminiak C, et al. Response to hepatitis B vaccine of persons positive for antibody to hepatitis B core antigen. Gastroenterology 1992; 103: 590-4.
83. Al-Mekhaizeem KA, Miriello M, Sherker AH. The frequency and significance of isolated hepatitis B core antibody and the suggested management of patients. CMAJ 2001; 165: 1063-4.
84. Almeida Neto C, Strauss E, Sabino EC, Sucupira MC, Chamone DA. Significance of isolated hepatitis B core antibody in blood from Sao Paulo. Rev Inst Med Trop Sao Paulo 2001; 43: 203-8.
85. Chlabicz S, Grzeszczuk A. Hepatitis B virus vaccine for patients with hepatitis C virus infection. Infection 2000; 28: 341-5.
86. Lee SD, Chan CY, Yu MI, Lu RH, Chang FY, Lo KJ. Hepatitis B vaccination in patients with chronic hepatitis C. J Med Virol 1999; 59: 463-8.
87. Wiedmann M, Liebert UG, Oesen H, et al. Decreased immunogenicity of recombinant hepatitis B vaccine in chronic hepatitis C. Hepatology 2000; 31: 230-4.
88. Rosman AS, Basu P, Galvin K, Lieber CS. Efficacy of a high and accelerated dose of hepatitis B vaccine in alcoholic patients: a randomized clinical trial. Am J Med 1997; 103: 217-22.
89. Keeffe EB, Krause DS. Hepatitis B vaccination of patients with chronic liver disease. Liver Transpl Surg 1998; 4: 437-9.
90. Mendenhall C, Roselle GA, Lybecker LA, et al. Hepatitis B vaccination. Response of alcoholic with and without liver injury. Dig Dis Sci 1998; 33: 263-9.
91. Bronowicki JP, Weber-Larivaille F, Gut JP, Doffoel M, Vetter D. Comparison of immunogenicity of vaccination and serovaccination against hepatitis B virus in patients with alcoholic cirrhosis. Gastroenterol Clin Biol 1997; 21: 848-53.
92. Villeneuve E, Vincelette J, Villeneuve JP. Ineffectiveness of hepatitis B vaccination in cirrhotic patients waiting for liver transplantation. Can J Gastroenterol 2000; 14(Suppl. B): 59B-62B.
93. Dominguez M, Barcena R, Garcia M, Lopez-Sanroman A, Nuno J. Vaccination against hepatitis B virus in cirrhotic patients on liver transplant waiting list. Liver Transpl 2000; 6: 440-2.
94. Arslan M, Wiesner RH, Sievers C, Egan K, Zein NN. Double-dose accelerated hepatitis B vaccine in patients with end-stage liver disease. Liver Transpl 2001; 7: 314-20.
95. Struve J, Aronsson B, Frenning B, Forsgren M, Weiland O. Seroconversion after additional vaccine doses to non-responders to three doses of intradermally or intramuscularly administered recombinant hepatitis B vaccine. Scand J Infect Dis 1994; 26: 468-70.